Conference
Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).
Abstract
185
Background: Threeprognosticrisk groups have been identified in men with mCRPC (good [GR]/intermediate [IR]/poor [PR]) based on 0-1, 2 or 3-4 factors (visceral disease, pain, anemia, bone scan progression). Prostate Cancer Working Group (PCWG)-2 defines clinical subtypes with visceral disease, bone metastases ± nodal metastases and nodal disease only. The prognostic ability of risk grouping or PCWG2 subtypes was evaluated …
Authors
Pond GR; Armstrong AJ; Wood BA; Brookes M; Leopold LH; Burke JM; Caton JR; Fleming MT; Sonpavde G
Volume
29
Pagination
pp. 185-185
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2011
DOI
10.1200/jco.2011.29.7_suppl.185
Conference proceedings
Journal of Clinical Oncology
Issue
7_suppl
ISSN
0732-183X